Sumitomo Mitsui Trust Holdings Inc. cut its position in ResMed Inc. (NYSE:RMD) by 1.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 379,209 shares of the medical equipment provider’s stock after selling 4,663 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 0.27% of ResMed worth $29,184,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of RMD. FMR LLC lifted its position in ResMed by 38.2% in the 2nd quarter. FMR LLC now owns 5,542,582 shares of the medical equipment provider’s stock valued at $431,601,000 after purchasing an additional 1,531,772 shares during the last quarter. Koch Industries Inc. lifted its position in ResMed by 17,065.2% in the 2nd quarter. Koch Industries Inc. now owns 985,796 shares of the medical equipment provider’s stock valued at $973,000 after purchasing an additional 980,053 shares during the last quarter. BlackRock Inc. lifted its position in ResMed by 6.8% in the 2nd quarter. BlackRock Inc. now owns 14,240,077 shares of the medical equipment provider’s stock valued at $1,108,877,000 after purchasing an additional 904,939 shares during the last quarter. Vanguard Group Inc. lifted its position in ResMed by 3.3% in the 2nd quarter. Vanguard Group Inc. now owns 11,914,671 shares of the medical equipment provider’s stock valued at $927,797,000 after purchasing an additional 378,964 shares during the last quarter. Finally, First Trust Advisors LP lifted its position in ResMed by 191.8% in the 2nd quarter. First Trust Advisors LP now owns 350,012 shares of the medical equipment provider’s stock valued at $27,255,000 after purchasing an additional 230,056 shares during the last quarter. Hedge funds and other institutional investors own 60.38% of the company’s stock.

ResMed Inc. (NYSE:RMD) traded down $0.30 during mid-day trading on Friday, hitting $84.97. 87,913 shares of the company’s stock were exchanged, compared to its average volume of 863,512. ResMed Inc. has a one year low of $57.76 and a one year high of $87.81. The company has a market cap of $12,100.15, a P/E ratio of 29.71, a price-to-earnings-growth ratio of 1.89 and a beta of 0.79. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86.

ResMed (NYSE:RMD) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 EPS for the quarter, hitting analysts’ consensus estimates of $0.66. ResMed had a net margin of 16.58% and a return on equity of 21.53%. The company had revenue of $523.66 million for the quarter, compared to the consensus estimate of $506.08 million. During the same period in the previous year, the firm earned $0.62 EPS. ResMed’s revenue was up 12.5% on a year-over-year basis. sell-side analysts anticipate that ResMed Inc. will post 3 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 14th. Shareholders of record on Thursday, November 9th will be given a dividend of $0.35 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.65%. ResMed’s dividend payout ratio (DPR) is 56.68%.

TRADEMARK VIOLATION WARNING: “Sumitomo Mitsui Trust Holdings Inc. Decreases Stake in ResMed Inc. (RMD)” was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/sumitomo-mitsui-trust-holdings-inc-decreases-stake-in-resmed-inc-rmd/1724233.html.

In related news, insider James Hollingshead sold 7,019 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $84.16, for a total value of $590,719.04. Following the sale, the insider now directly owns 66,409 shares in the company, valued at approximately $5,588,981.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $76.74, for a total transaction of $1,534,800.00. Following the completion of the sale, the director now owns 314,800 shares in the company, valued at $24,157,752. The disclosure for this sale can be found here. Insiders have sold a total of 208,253 shares of company stock worth $16,930,356 over the last 90 days. 1.77% of the stock is owned by insiders.

Several analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of ResMed from a “sell” rating to a “hold” rating in a research report on Monday, October 30th. J P Morgan Chase & Co lifted their price objective on shares of ResMed from $72.00 to $73.00 and gave the company an “overweight” rating in a research report on Monday, October 30th. BMO Capital Markets lifted their price objective on shares of ResMed from $70.00 to $74.00 and gave the company a “market perform” rating in a research report on Friday, October 27th. Barclays PLC lifted their price objective on shares of ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a research report on Friday, October 27th. Finally, Northland Securities reiterated a “sell” rating and issued a $55.00 price objective on shares of ResMed in a research report on Friday, October 27th. Four investment analysts have rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. ResMed presently has a consensus rating of “Hold” and an average price target of $67.57.

ResMed Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.